𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose thiotepa and hematopoietic stem cell transplantation in pediatric malignant mesenchymal tumors: a phase II study

✍ Scribed by Lafay-Cousin, L; Hartmann, O; Plouvier, P; Méchinaud, F; Boutard, P; Oberlin, O

Book ID
110012739
Publisher
Nature Publishing Group
Year
2000
Tongue
English
Weight
55 KB
Volume
26
Category
Article
ISSN
0007-1188

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of high-dose thiotepa with
Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors
✍ Pession, Andrea; Prete, Arcangelo; Locatelli, Franco; Bella, Santiago; Melchiond 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

Background. The aim of this phase I study was to define the maximum tolerated dose (MTD) of thiotepa (TT), administered with busulfan (BU) 480 mg/m 2 and etoposide 2,400 mg/m 2 , followed by autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (APBSCT) support

A phase II study of ondansetron as antie
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation
✍ V. Barbounis; G. Koumakis; M. Vassilomanolakis; H. Hatzichristou; S. Tsousis; A. 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 651 KB

The field of high-dose chemotherapy with stem cell transplantation has been expanded recently as a treatment for solid tumors and hematological malignancies. Severe emesis remains one of the main extramedullary side-effects of high-dose regimens during the first week of treatment. Traditional antiem